A miR-19 regulon that controls NF-κB signaling
Michael P. Gantier(Hudson Institute of Medical Research), Bryan R.G. Williams(Monash University), Maria Kaparakis‐Liaskos(Monash Institute of Medical Research), Mark A. Behlke(Integrated DNA Technologies (United States)), Eric F. Morand(Novartis (Switzerland)), Soroush T. Sarvestani(Monash Institute of Medical Research), Die Wang(Monash Institute of Medical Research), H. James Stunden(University Hospital Bonn), Sinéad C. Corr(Trinity College Dublin), Dakang Xu(Hangzhou Normal University), Yuan Yang(Monash University), Claire E. McCoy(Royal College of Surgeons in Ireland)
Cited by 174
Related Papers
Interferon-inducible antiviral effectors
|Nature reviews. Immunology|2008|2.2k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells
|Nature Medicine|2018|796
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728